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Abstract  
 
Background: Greater height has been associated with increased risk of several cancers, but 
epidemiological data on height and pancreatic cancer are inconclusive. We conducted a 
systematic review and meta-analysis of prospective studies to clarify these results.  
  
Methods: PubMed and several other databases were searched up to September 2011. 
Prospective studies that reported relative risk (RR) estimates and 95% confidence intervals 
(CIs) associated with height and pancreatic cancer were included. Summary relative risks 
were estimated by use of a random effects model. 
 
Results: We identified ten cohort studies that were included in the meta-analysis. The 
summary RR for high vs. low height was 1.27 (95% CI: 1.12-1.45, I
2
=33%) and in the dose-
response analysis the summary RR per 5 cm increase in height was 1.09 (95% CI: 1.05-1.15, 
I
2
=61%). The results were similar among men and women, summary RR=1.07 (95% CI: 
1.01-1.14, I
2
=52%) and summary RR=1.09 (95% CI: 1.01-1.18, I
2
=59%), respectively. There 
was indication of small study bias with Egger’s test, p=0.05. The summary estimate was 
attenuated when we included results from two pooled analyses together with these studies, 
summary RR = 1.04 (95% CI: 1.01-1.07, I
2
=44%, pheterogeneity=0.08) and Egger’s test was no 
longer significant, p=0.17. 
 
Conclusions: This meta-analysis of cohort studies provides support that greater adult attained 
height is associated with increased risk of pancreatic cancer. Although the strength of the 
association may have been overestimated due to publication bias, the positive association 
persisted in several sensitivity analyses taking this into account. 
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Introduction 
Pancreatic cancer is the 9
th
 most common cause of cancer with 277 000 new cases 
diagnosed in 2008 worldwide, accounting for about 2.2% of all cancer cases (1). There are 
few early symptoms of the disease and it is usually diagnosed in the later stages. Because of 
this, survival among pancreatic cancer patients is very low, on average only 6 months after 
the diagnosis (2). Established risk factors include tobacco smoking, which explains about 20-
25% of pancreatic cancer cases (3, 4), family history of pancreatic cancer (5), pancreatitis (6), 
diabetes (relative risk, RR=1.8) (7) and body fatness (RR=1.10 per 5 kg/m
2
) (8).  
Tall people are at increased risk of several cancers (9, 10), but the evidence relating 
height to pancreatic cancer risk is not convincing (9). Both genetic and environmental factors 
determines adult attained height, which is partly a surrogate marker for in utero and 
childhood conditions (11). Adult height is related to birth weight, rate of growth, and age of 
puberty and periods of peak growth, such as in infancy and adolescence, are particularly 
important in determining adult height (12). Undernutrition and infectious diseases are the 
most important non-genetic factors affecting growth and adult body height, and as the 
prevalence of these conditions  is reduced, an increase in height is observed (11).  
 The World Cancer Research Fund/American Institute for Cancer Research report 
from 2007 stated that greater height probably was associated with increased risk of pancreatic 
cancer (9), however, studies published subsequent to this report have reported inconsistent 
results. The large European Prospective Investigation into Nutrition and Cancer reported a 
74% increase in pancreatic cancer risk comparing those with the highest with the lowest 
height (13). However, other large studies (10, 14-17) and  three pooled analyses (18-20) did 
not find a significant association between greater height and pancreatic cancer risk. To clarify 
these findings we conducted a systematic review and dose-response meta-analysis of 
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prospective cohort studies of adult height and pancreatic cancer risk. In particular we wanted 
to clarify the dose-response relationship and explore potential heterogeneity by conducting 
subgroup and meta-regression analyses.  
 
Methods  
Data sources and searches 
The literature search and data extraction up to December 2005 was conducted by 
several reviewers at University of Leeds. Initially several databases were searched including 
Pubmed, Embase, CAB Abstracts, ISI Web of Science, BIOSIS, LILACS, Cochrane library, 
CINAHL, AMED, National Research Register, and In Process Medline. Because all the 
relevant studies were identified through searches in PubMed a change in the protocol was 
made and only PubMed was used for the updated searches from January 2006 to September 
2011. A predefined protocol was followed for the review 
(http://www.dietandcancerreport.org/downloads/SLR_Manual.pdf) and includes details of the 
search terms. Standard criteria for conducting and reporting meta-analyses were followed 
(21).  We also searched the reference lists of all the studies that were included in our analysis 
to identify any further studies. 
 
Study selection 
To be included, the study had to have a prospective cohort, case-cohort or nested 
case-control study design and to investigate the association between physical activity and 
pancreatic cancer risk. Estimates of the relative risk (hazard ratio, risk ratio) had to be 
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available with the 95% confidence intervals in the publication. For the dose-response 
analysis, a quantitative measure of height had to be provided. We identified 18 possibly 
relevant publications in the search (10, 13-17, 22-33). Two publications that only provided 
mean height among cases and controls were excluded (27, 30), two duplicate publications 
were excluded (29, 31) and one publication which did not provide any risk estimates was 
excluded (28). Each study was only included once in the main analysis or in the subgroup 
analyses, but for some studies overlapping publications provided results which were not 
available in the publication used for the main analysis, and these were used for some of the 
subgroup analyses. One of the remaining publications was only included in the subgroup 
analysis by gender (26) because a superseding publication (which was included in the overall 
analysis) only reported results for men and women combined (15) and two other publications 
(32, 33) were only included in the subgroup analysis of pancreatic cancer mortality as a 
publication from the same study with a larger number of cases was included in the overall 
analysis (15). 
 
Data extraction and Quality Assessment 
The following data were extracted from each study: The first author’s last name, 
publication year, country where the study was conducted, the study name, follow-up period, 
sample size, gender, age, number of cases, height assessment method (self-reported vs. 
measured), comparison of high vs. low height in cm, RRs and 95% CIs for the highest vs. the 
lowest level of intake and variables adjusted for in the analysis. The search and data 
extraction up to December 2005 was conducted by JEC, DSMC, VB and several other 
reviewers at the University of Leeds. These data were checked for accuracy by DA. The 
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search and data extraction from January 2006 to September 2011 was conducted by DA and 
was checked for accuracy by TN.  
 
Data Synthesis and Analysis 
We used random effects models to calculate summary RRs and 95% CIs for the 
highest vs. the lowest height and for the dose-response analyses (34). The average of the 
natural logarithm of the RRs was estimated and the RR from each study was weighted by the 
inverse of its variance. A two-tailed p<0.05 was considered statistically significant.  
For the dose-response analyses we used the method by Greenland and Longnecker 
(35) to compute study-specific slopes (linear trends) and 95% CIs from the natural logs of the 
RRs and CIs across categories of height. The method requires that the distribution of cases 
and person-years or non-cases and the RRs with the variance estimates for at least three 
quantitative exposure categories are known. We estimated the distribution of cases or person-
years in studies that did not report these, but reported the total number of cases/person-years, 
for example, the total number of person-years was divided by 5 when data were analyzed by 
quintiles in order to derive the number of person-years in each quintile. The Chene and 
Thompson method was used to calculate the mean level of height in each category (36). The 
dose-response results in the forest plots are presented for a 5 cm increment in height. We 
examined a potential non-linear dose-response relationship by using fractional polynomial 
models (37). The best fitting second order fractional polynomial regression model was 
determined, defined as the one with the lowest deviance. A likelihood ratio test was used to 
assess the difference between the non-linear and linear models to test for nonlinearity (38). 
Heterogeneity between studies was assessed by the Q test and I
2
 (a measure of the 
proportion of total variation in study estimates that is due to heterogeneity) (39). Subgroup 
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and meta-regression analyses by sex, duration of follow-up, number of cases, geographic 
location and adjustment for confounding factors such as alcohol, smoking, diabetes, body 
mass index, physical activity energy intake were conducted to investigate potential sources of 
heterogeneity. Small study effects, such as publication bias, was assessed by inspection of the 
funnel plots and with Egger’s test (40) and with Begg’s test (41), and the results were 
considered to indicate small study effects when p<0.10. We conducted sensitivity analyses 
excluding one study at a time to clarify whether the results were simply due to one large 
study or a study with an extreme result. In addition, results from three pooled analyses were 
included together with the identified studies in a sensitivity analysis (18-20).  
 
Results 
We identified 10 cohort studies (13 publications) that were included in the analysis of 
height and pancreatic cancer risk (10, 13-17, 22-26, 32, 33) (Table 1, Figure 1). One of the 
publications were only included in subgroup analyses by sex (26) and two were only included 
in the subgroup analysis of mortality (32, 33). One publication reported results from two 
cohort studies (24). Seven studies were from Europe, two from North-America and one from 
South Korea (Table 1).  
 
Height 
High vs. low analysis 
Nine cohort studies (eight publications) (13-17, 23-25) were included in the high vs. 
low analysis of height and pancreatic cancer risk and included 5273 cases among 2635802 
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participants. The summary RR for all studies was 1.27 (95% CI: 1.11-1.48), with low 
heterogeneity, I
2
=33% and pheterogeneity=0.15 (Figure 2).  
 
Dose-response analysis 
Nine cohort studies (eight publications) (10, 13-16, 22, 24, 25) were included in the 
dose-response analysis and included 5914 cases among 2602498 participants. The summary 
RR per 5 cm increase in height was 1.09 (95% CI: 1.05-1.15), with high heterogeneity, 
I
2
=61% and pheterogeneity=0.009 (Figure 3). The summary RR ranged from 1.08 (95% CI: 1.04-
1.13) when excluding the Nurses’ Health Study to 1.11 (95% CI: 1.05-1.17) when excluding 
the Million Women’s Study. There was some indication of small study effects with Egger’s 
test, p=0.05, but not with Begg’s test, p=0.35. There was no evidence for a nonlinear 
association between height and pancreatic cancer risk, pnonlinearity=0.21 (Figure 4).  
 
Subgroup, meta-regression and sensitivity analyses  
In subgroup analyses, the results were consistent when stratified by gender and 
geographic location, but there was some indication of heterogeneity when stratified by 
number of cases (pheterogeneity=0.03) and adjustment for diabetes (pheterogeneity=0.02). There was 
a weaker association among studies with a larger number of cases than among studies with a 
low number of cases, but the association was stronger among studies that adjusted for 
diabetes, than for studies without such adjustment (Table 2). Excluding one study of 
mortality (25) did not affect the results, summary RR= 1.10 (95% CI: 1.05-1.16, I
2
=65%, 
pheterogeneity=0.006) (Table 2). Restricting the analysis to four studies of mortality (17, 25, 32, 
33) resulted in a summary RR of 1.04 (95% CI: 1.00-1.07, I
2
=0%, pheterogeneity=0.84) (Table 
2).  
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We also conducted additional sensitivity analyses including data from the Pooling 
Project of Prospective Studies (835340 participants and 2135 cases) (18) in the analysis (RR 
per 5 cm= 1.02, 95% CI: 0.97-1.06 for men and 1.00, 95% CI: 0.95-1.06) for women), 
excluding the three cohorts (Health Professional’s Follow-up Study, Nurses’s Health Study, 
and Netherlands Cohort Study) in our analysis that were included in the pooled analysis. The 
summary RR was 1.04 (95% CI: 1.01-1.08, I
2
=55%, pheterogeneity=0.04) per 5 cm increase in 
height and 1.16 (95% CI: 1.06-1.26, I
2
=6%, pheterogeneity=0.38) in the high vs. low analysis 
(Supplementary Figure 1). When we included the results from the Asian Pacific Cohort 
Studies Collaboration (506648 participants and 294 deaths) (20) in our analysis (HR=1.08, 
95% CI: 0.94-1.24 for men and HR=0.99, 95% CI: 0.82-1.21 for women per 6 cm increase in 
height), the summary RR was 1.08 (95% CI: 1.04-1.13, I
2
=55%, pheterogeneity=0.01) per 5 cm 
increase in height. When we included both these pooled analyses together with our analyses 
and excluding the overlapping studies the summary RR was 1.04 (95% CI: 1.01-1.07, 
I
2
=43%, pheterogeneity=0.08) and Egger’s test was no longer significant, p=0.18 (Supplementary 
figure 2). In an additional sensitivity analysis we included the results from the Pancreatic 
Cancer Cohort Consortium (2170 cases and 2209 controls) (19) in the high vs. low analysis 
(OR = 1.08, 95% CI: 0.83-1.41 for men and 0.95, 95% CI: 0.74-1.21 for women) and 
excluding the overlapping studies the summary RR for high vs. low height was 1.10 (95% CI: 
1.00-1.20, I
2
=0%, pheterogeneity=0.88) (Supplementary Figure 3).  
 
Discussion 
We found a weak positive association between height and pancreatic cancer risk, 
which was present both among men and women in stratified analyses.  
11 
 
 Our meta-analysis may have several limitations which must be taken into 
consideration. The possibility of confounding from other risk factors cannot be ruled out. 
Although, the results persisted in subgroup analyses of studies that adjusted for the most 
important confounding factors such as smoking, diabetes and BMI, fewer studies had 
adjusted for other potential confounding factors. There was evidence of small study effects in 
our analysis and if this is due to publication bias it may have led to exaggerated risk 
estimates. Our results are in contrast to those of three pooled analyses (18-20), which found 
no significant association between height and pancreatic cancer risk, but included more than 
twice as many cases and more than three times as many participants as the two largest of 
these (18, 19). Although some of the studies included in our analysis overlapped with some 
of the pooled analyses (13, 14, 16, 24), several cohort studies (10, 15, 22, 23, 25) not 
included in the pooled analyses may have driven the overall result towards an increased risk 
in our analysis. However, a number of the studies included in the pooling projects have not 
yet published on height and pancreatic cancer individually. In several sensitivity analyses we 
added the pooled results of the Pooling Project of Prospective Studies (18), the Asian Pacific 
Cohort Studies Collaboration (20) and the Pancreatic Cancer Cohort Consortium (19) to our 
analyses, and although the results were attenuated there was still a significant positive 
association. This suggests that the summary estimate from our primary analysis may have 
been overestimated, but may not entirely be due to publication bias. Publication bias may 
have occurred because several of the individual studies contributing to the pooled analyses 
may have had moderate sample sizes and possibly insufficient statistical power to detect an 
association with a relatively uncommon cancer such as pancreatic cancer. In addition, it may 
not have been a priority in more modest sized cohorts to investigate a non-modifiable risk 
factor for pancreatic cancer.  
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 Measurement errors in the assessment of height may have influenced the results. 
Several studies have reported high correlations between measured and self-reported height 
(42-44). Although in our analyses studies using self-reported height reported higher estimates 
than studies using measured height, there was no evidence of heterogeneity between these 
subgroups, suggesting that this may have been due to chance variation.  
 Although increased height is an established risk factor for colorectal and breast cancer 
and a possible risk factor for several other cancers (9, 10) the specific mechanism(s) that may 
explain an association between greater height and pancreatic cancer risk is not clear. It is also 
possible that common mechanisms may underlie the association between height and several 
cancers including pancreatic cancer. Adult height reaches its maximum between age 20 and 
30 years and both childhood and adolescent dietary factors and infections are thought to be of 
importance (45, 46). Particularly elevated levels of insulin-like growth factor-1 (IGF-1) may 
play an important role in determining growth and may also influence cancer risk. Higher 
IGF-1 levels in childhood is associated with childhood growth (47). Insulin-like growth 
factors may contribute to cancer risk by stimulating proliferation, adhesion, and cell 
migration and by inhibiting apoptosis (48). However, greater concentrations of circulating 
IGF-1 in adulthood has not been significantly associated with pancreatic cancer risk in 
epidemiological studies (30, 49-51), but if the relevant time period of exposure is in 
childhood or adolescence this could explain the lack of association reported in these studies. 
At last, taller people have a greater number of cells and thus a greater probability of 
mutations leading to malignancy.  
Our meta-analysis also has several strengths. Because we based our analyses on 
prospective studies we have effectively avoided recall and selection bias. The large sample 
size and large number of cases provided statistical power to detect moderate associations. In 
addition, we conducted more detailed subgroup and sensitivity analyses than what has been 
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done previously and we assessed the dose-response relationship using both linear and 
nonlinear models. In sensitivity analyses, we included the results of pooled analyses to 
increase the number of cohort studies contributing information. We have therefore obtained a 
more precise estimate than in the primary analyses. However, it has to be noted that including 
pooled results does not allow to properly assess heterogeneity. Nevertheless, the one pooled 
analysis that reported on heterogeneity found no evidence of heterogeneity across studies so 
this should be less of a concern (18).  
 In conclusion, our results indicate that greater height is associated with increased risk 
of pancreatic cancer. Although the strength of the association may have been overestimated 
due to publication bias, the positive association persisted in several sensitivity analyses taking 
this into account.  
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Table 1: Prospective studies of height and pancreatic cancer risk 
 
Author, 
publication 
year, country/ 
region 
Study name Follow-up 
period 
Study size, 
gender, age, 
number of cases 
Assessment of 
height 
Exposure  Level RR (95% CI) Adjustment for confounders 
Green J et al, 
2011, United 
Kingdom 
The Million 
Women Study 
1996-2001 – 
2008, 11.7 
million 
person-years 
1297124 women, 
age: 2044 cases 
Self-reported Height Per 10 cm increase 1.05 (0.95-1.17) Age, region, SES, smoking, alcohol 
intake, BMI, strenuous exercise, 
age at menarche, parity, age at 1
st
 
birth 
Stevens RJ et 
al, 2009, 
United 
Kingdom 
The Million 
Women Study 
1996/2001-
2006/2007, 
7.2 years 
follow-up  
1290000 women, 
age 50-64 years: 
1338 cases 
1710 deaths 
Self-reported Height, incidence 
Height, mortality 
≥170 vs. <155 cm 
≥170 vs. <155 cm 
1.11 (0.95-1.27) 
1.09 (0.95-1.25) 
Age, region, SES, BMI 
Meinhold CL 
et al, 2009, 
Finland 
ATBC Cancer 
Prevention 
Study 
1985/1988 – 
2004, 19.4 
years 
follow-up 
27035 smoking 
men, age 50-69 
years: 305 cases 
Measured  Height 182 vs. 167 cm 1.23 (0.87-1.75) Age, BMI, cigarettes per day, years 
of smoking, total energy, DM 
Sung J et al, 
2009, South 
Korea 
Korea Medical 
Insurance 
Corporation 
Study 
1994 – 2003,  
8.7 years 
follow-up 
449214 men and 
339575 women, 
age 40-64 years: 
920/334 cases 
Measured Height, men 
 
Height, women 
>171 vs. ≤151 cm 
Per 5 cm 
>158 vs. ≤151 cm 
Per 5 cm 
0.98 (0.81-1.19) 
0.99 (0.93-1.06) 
1.12 (0.80-1.57) 
1.03 (0.92-1.14) 
Age, BMI, cigarette smoking, 
alcohol, regular exercise, monthly 
salary, occupation, area of 
residence 
Song YM et 
al, 2008, 
South Korea 
Korea Medical 
Insurance 
Corporation 
Study 
1993/1994 – 
2004, 9.86 
years 
follow-up 
344519 women, 
age 40-64 years: 
239 deaths 
Measured  Height  ≥161 cm vs. <149 cm 1.22 (0.71-2.09) 
0.99 (0.87-1.13) 
Age, SBP, serum cholesterol, 
fasting blood glucose, BMI, 
cigarette smoking, alcohol, regular 
exercise, monthly salary, 
occupation, area of residence 
Berrington de 
Gonzalez A et 
al, 2008, 
South Korea 
Korea Medical 
Insurance 
Corporation 
Study 
1992/1995-
2005, 12 
years 
follow-up 
631172 men and 
women, age ≥45 
years: 2194 cases 
Measured  Height  ≥171/≥158 vs. <162/<148 cm 1.09 (0.94-1.25) Age, sex, smoking, fasting serum 
glucose levels 
Verhage BA et 
al, 2007, 
Netherlands 
Netherlands 
Cohort Study 
1986-1999, 
13.3 years 
follow-up 
4774 men and 
women, age 55-69 
years: 446 cases 
Self-reported Height, men 
 
Height, women 
188 vs. 166.1 cm 
Per cm 
177 vs. 155.7 cm 
Per cm 
0.99 (0.56-1.75) 
1.01 (0.99-1.03) 
1.32 (0.67-2.60) 
1.02 (1.00-1.05) 
Age, smoking, number of cigarettes 
per day, number of years smoked, 
DM, history of hypertension 
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Berrington de 
Gonzalez AB 
et al, 2006, 
Europe (EPIC) 
European 
Prospective 
Investigation 
into Nutrition 
and Cancer 
1991/2000- 
2004, 6.5 
years 
follow-up 
438405 men and 
women, age 19-84 
years: 324 cases 
Measured and 
self-reported 
Height ≥180/≥167 vs. <170/<158 cm 
(m/w) 
Per 10 cm 
1.74 (1.20-2.52) 
 
1.37 (1.15-1.64) 
Age, sex, country, smoking, 
diabetes 
Batty GD et 
al, 2006, 
United 
Kingdom 
The Whitehall 
Study 
 
1967/1970 – 
2002, ~30 
years 
follow-up 
17353 men, age 
40-64 years: 150 
deaths 
Measured  Height ≥181 vs. <171 cm 
Per 5 cm 
1.26 (0.71-2.22) 
1.02 (0.90-1.15) 
Age, employment grade, physical 
activity, smoking habit, marital 
status, BMI, triceps skinfold 
thickness, SBP, cholesterol, IGT, 
DM, disease at entry 
Song YM et 
al, 2003, 
South Korea 
Korea Medical 
Insurance 
Corporation 
Study 
1992 – 1998, 
~6 years 
follow-up 
386627 men, age 
40-64 years: 276 
deaths 
Measured Height  ≥175 vs. ≤162 cm 
Per 5 cm 
1.09 (0.65-1.84) 
1.07 (0.95-1.20) 
Age, DBP, glucose, cholesterol, 
BMI, alcohol, smoking, exercise 
Michaud DS 
et al, 2001, 
USA 
Nurses’ 
Health Study 
1976-1996, 
20 years 
follow-up 
117041 women, 
age 30-55 years: 
210 cases 
Self-reported Height  >167.6 vs. <157.5 cm 1.77 (1.15-2.72) Age, BMI at baseline, pack-years of 
smoking, DM, cholecystectomy 
Michaud DS 
et al, 2001, 
USA 
Health 
Professionals 
Follow-up 
Study 
1986-1998, 
12 years 
follow-up 
 
46648 men, age 
40-75 years: 140 
cases 
Self-reported Height ≥185.4 vs. ≤172.7 cm 1.88 (1.14-3.11) Age, BMI at baseline, pack-years of 
smoking, DM, cholecystectomy 
Lund Nilsen 
TI et al, 2001, 
Norway 
Nord 
Trondelag 
Health Survey 
1984-1986 – 
1996, 12 
years 
follow-up 
31000 men and 
32374 women, 
age ≥30 years:166 
cases 
Measured Height, men 
Height, women 
>176 vs. ≤176 cm 
>162 vs. ≤162 cm 
1.09 (0.70-1.71) 
1.36 (0.81-2.29) 
Age  
Tulinius H et 
al, 1997, 
Iceland 
The Reykjavik 
Study 
1968-1995, 
4-27 years 
follow-up 
11580 women and 
11366 men, age  
years: 36/65 cases 
Measured  Height, men 
Height, women 
Per cm 
Per cm 
1.035 (0.994-1.078) 
1.055 (0.993-1.120) 
Age  
BMI=Body Mass Index, DBP = diastolic blood pressure, DM = diabetes mellitus, FH=Family history, IGT=impaired glucose tolerance, SBT=systolic blood pressure, SES = 
socioeconomic status 
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Table 2: Subgroup analyses of height and pancreatic cancer, dose-response analysis 
 Height 
 n RR (95% CI) I
2
 (%) Ph
1 
Ph
2
 
All studies 9 1.09 (1.05-1.15) 60.9 0.009  
Sex       
    Men  6 1.07 (1.01-1.14) 52.1 0.06 0.76/ 
0.75* 
    Women 5 1.09 (1.01-1.18) 59.0 0.05 
    Men and women 2 1.09 (0.97-1.23) 83.6 0.01 
Outcometype       
    Incidence 8 1.10 (1.05-1.16) 64.7 0.006 0.15 
    Mortality 4 1.04 (1.00-1.07) 0 0.84 
Measured or self-reported height      
    Self-reported 4 1.08 (1.04-1.13) 71.3 0.02 0.94 
    Measured  4 1.04 (1.01-1.08) 20.6 0.29 
    Self-reported & measured 1 1.17 (1.07-1.28)   
Duration of follow-up      
22 
 
    <10 yrs follow-up 1 1.17 (1.07-1.28)   0.32 
    ≥10 yrs follow-up 8 1.08 (1.04-1.13) 56.9 0.02 
Geographic location       
    Europe 6 1.09 (1.03-1.16) 59.8 0.03 0.69 
    America 2 1.17 (1.08-1.27) 0 0.38 
    Asia 1 1.03 (0.99-1.08)   
Number of cases      
    Cases <250 4 1.14 (1.05-1.23) 39.5 0.18 0.03 
    Cases 250-<500 3 1.13 (1.06-1.19) 27.5 0.25 
    Cases ≥500 2 1.03 (1.00-1.06) 0 0.79 
Adjustment for potential confounders 
Alcohol  Yes  1 1.02 (0.97-1.08)   0.24 
No  8 1.11 (1.05-1.17) 58.6 0.02 
Smoking  
 
Yes  8 1.09 (1.04-1.14) 61.1 0.01 0.29 
No  1 1.22 (1.03-1.45)   
Diabetes  Yes  6 1.12 (1.07-1.18) 26.9 0.23 0.02 
23 
 
No  3 1.05 (0.99-1.10) 49.3 0.14 
Body mass index Yes  5 1.08 (1.01-1.14) 52.5 0.08 0.46 
No  4 1.12 (1.04-1.22) 73.8 0.01 
Physical activity  
 
Yes  2 1.02 (0.98-1.07) 0 0.95 0.13 
No  7 1.12 (1.06-1.18) 62.2 0.01 
Energy intake Yes  1 1.05 (0.95-1.16)   0.58 
No  8 1.10 (1.05-1.16) 65.6 0.005 
n denotes the number of studies, 
1
P for heterogeneity within each subgroup, 
2
 P for heterogeneity between subgroups with meta-regression analysis. 
*P for heterogeneity between men and women
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Figure 1. Flow-chart of study selection 
 
 
 
 
 
 
 
 
 
22267 hits yielded from multiple electronic 
bibliographic databases and hand-searching 
18396 hits from WCRF 2
nd
 Expert Report 
(≤2005) 
3873 hits from the Continuous Update (1
st
 
January 2006 - 28
th
 September 2011) 
637 full-text articles retrieved and assessed for 
inclusion 
378 publications included in the WCRF systematic 
literature review 
18 publications from prospective studies reporting 
on the association between height and pancreatic 
cancer and potentially suitable for inclusion in the 
meta-analysis 
 
  
 
21630 excluded on the basis of title and abstract 
259 articles excluded for not fulfilling the inclusion 
criteria 
256 did not report on the associations of 
interest (not relevant exposure or outcome, 
mechanistic study, diagnostic study) or did not 
contain original data  
(articles/commentary/reviews) 
3 full text articles were not retrieved 
5 Excluded publications 
       2 reported only mean height 
       2 duplicate publication excluded  
       1 publication did not report risk estimates 
 
360 publications excluded for reporting on 
exposures other than height and pancreatic cancer 
and/or study type other than prospective study 
13 publications from 10 cohort studies were 
included in the meta-analysis of height and 
pancreatic cancer risk 
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Figure 2. Height and pancreatic cancer, high vs. low analysis 
 
Figure 3. Height and pancreatic cancer, per 5 cm 
 
 
  Relative Risk
 .25  .5  .75  1  2  3  4
 Study
 Relative Risk
 (95% CI)
 Meinhold, 2009   1.23 ( 0.87, 1.75)
 Stevens, 2009   1.18 ( 0.97, 1.44)
 Berrington de Gonzalez, 2008   1.09 ( 0.94, 1.25)
 Verhage, 2007   1.12 ( 0.72, 1.72)
 Berrington de Gonzalez, 2006   1.74 ( 1.20, 2.52)
 Batty, 2006   1.27 ( 0.71, 2.22)
 Michaud, 2001, HPFS   1.88 ( 1.14, 3.11)
 Michaud, 2001, NHS   1.77 ( 1.15, 2.72)
 Nilsen, 2000   1.20 ( 0.85, 1.68)
 Overall   1.27 ( 1.12, 1.45)
  Relative Risk
 .75  1  1.25  1.5
 Study
 Relative Risk
 (95% CI)
 Green, 2011   1.02 ( 0.97, 1.08)
 Meinhold, 2009   1.05 ( 0.95, 1.16)
 Berrington de Gonzalez, 2008   1.03 ( 0.99, 1.08)
 Verhage, 2007   1.14 ( 1.06, 1.24)
 Berrington de Gonzalez, 2006   1.17 ( 1.07, 1.28)
 Batty, 2006   1.02 ( 0.90, 1.15)
 Michaud, 2001, HPFS   1.12 ( 0.99, 1.27)
 Michaud, 2001, NHS   1.21 ( 1.08, 1.34)
 Tulinius, 1997   1.22 ( 1.03, 1.45)
 Overall   1.09 ( 1.05, 1.15)
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Figure 4: Height and pancreatic cancer, nonlinear dose-response 
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Supplementary figure 1: Height and pancreatic cancer risk, including the Pooling Project of 
Prospective Studies (Genkinger, 2011), high vs. low analysis 
Supplementary figure 2: Height and pancreatic cancer risk, including Pooling Project of Prospective 
Studies (Genkinger, 2011) and the Asia Pacific Cohort Studies Collaboration (Batty, 2009), per 5 cm 
  
  Relative Risk
 .5  .75  1  1.25  1.5  2  2.5
 Study
 Relative Risk
 (95% CI)
 Genkinger, 2011, men   1.20 ( 0.96, 1.51)
 Genkinger, 2011, women   1.06 ( 0.87, 1.29)
 Stevens, 2009   1.18 ( 0.97, 1.44)
 Berrington de Gonzalez, 2008   1.09 ( 0.94, 1.25)
 Batty, 2006   1.27 ( 0.71, 2.22)
 Berrington de Gonzalez, 2006   1.74 ( 1.20, 2.52)
 Nilsen, 2000   1.20 ( 0.85, 1.68)
 Overall   1.16 ( 1.06, 1.26)
  Relative Risk
 .75  1  1.25  1.5
 Study
 Relative Risk
 (95% CI)
 Genkinger, 2011, men   1.02 ( 0.97, 1.06)
 Genkinger, 2011, women   1.00 ( 0.95, 1.06)
 Green, 2011   1.02 ( 0.97, 1.08)
 Batty, 2009, men   0.99 ( 0.88, 1.11)
 Batty, 2009, men   1.07 ( 0.95, 1.20)
 Berrington de Gonzalez, 2008   1.03 ( 0.99, 1.08)
 Batty, 2006   1.02 ( 0.90, 1.15)
 Berrington de Gonzalez, 2006   1.17 ( 1.07, 1.28)
 Tulinius, 1997   1.22 ( 1.03, 1.45)
 Overall   1.04 ( 1.01, 1.07)
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Supplementary figure 3: Height and pancreatic cancer risk, including PANSCAN (Arslan, 2009), 
high vs. low analysis 
 
  Relative Risk
 .5  .75  1  1.25  1.5  2  2.5
 Study
 Relative Risk
 (95% CI)
 Arslan, 2009, men   1.08 ( 0.83, 1.41)
 Arslan, 2009, women   0.95 ( 0.74, 1.21)
 Stevens, 2009   1.18 ( 0.97, 1.44)
 Berrington de Gonzalez, 2008   1.09 ( 0.94, 1.25)
 Verhage, 2007   1.12 ( 0.72, 1.72)
 Batty, 2006   1.27 ( 0.71, 2.22)
 Nilsen, 2000   1.20 ( 0.85, 1.68)
 Overall   1.10 ( 1.00, 1.20)
